[go: up one dir, main page]

PE66798A1 - ANALOGS OF VITAMIN D3 TREATED WITH FLUORINE - Google Patents

ANALOGS OF VITAMIN D3 TREATED WITH FLUORINE

Info

Publication number
PE66798A1
PE66798A1 PE1997000387A PE00038797A PE66798A1 PE 66798 A1 PE66798 A1 PE 66798A1 PE 1997000387 A PE1997000387 A PE 1997000387A PE 00038797 A PE00038797 A PE 00038797A PE 66798 A1 PE66798 A1 PE 66798A1
Authority
PE
Peru
Prior art keywords
link
compounds
carbon
double
analogs
Prior art date
Application number
PE1997000387A
Other languages
Spanish (es)
Inventor
Milan Radoje Uskokovic
Percy Sarwood Manchand
Jr John Joseph Nestor
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE66798A1 publication Critical patent/PE66798A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: "X" ES =CH2 O SON HIDROGENO; R1 Y R2 SON DE PREFERENCIA H, CF3 O CH3, o R1 Y R2 JUNTO CON EL CARBONO 20 FORMAN UN CICLOFLUOROALQUILO O CICLOALQUILO C3-C6, o R1 Y R2 JUNTOS FORMAN =CH2; R3 Y R4 SON DE PREFERENCIA CH3, CF3, CH2CH3, CH2CF3, CF2CH3 Y CF2CF3 o R3 Y R4 JUNTO CON EL CARBONO 25 FORMAN UN CICLOFLUOROALQUILO O CICLOALQUILO C3-C9; "A" ES UN ENLACE SIMPLE O DOBLE; "B" ES UN ENLACE DOBLE O TRIPLE; SIEMPRE QUE: CUANDO "X" ES =CH2, "A" ES UN ENLACE DOBLE, Y: (i) R3 Y R4 SON CF3: SI UNO DE R1 Y R2 ES H, ENTONCES, EL OTRO NO ES CH3; (ii) R3 Y R4 SON ALQUILO C1-C2: SI R2 ES H, ENTONCES, R1 NO ES CH3; (iii) R3 Y R4 SON ALQUILO C1-C4: SI R1 ES H, ENTONCES, R2 NO ES CH3; (iv) R1 ES CH3, R2 ES H: SI UNO DE R3 Y R4 ES CF3, ENTONCES, EL OTRO NO ES CH3; (v) CUANDO "X" SEAN H, R3 Y R4 SON CF3, "A" ES UN ENLACE DOBLE, "B" ES UN ENLACE TRIPLE: SI R2 ES H, ENTONCES, R1 NO ES CH3. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DE LOS COMPUESTOS (I), QUE COMPRENDE ELIMINAR LOS GRUPOS PROTECTORES SILILO; Y A LOS COMPUESTOS INTERMEDIOS DE FORMULA (II), EN DONDE: R1 Y R2 SON CH3 o JUNTO CON EL CARBONO 20 FORMAN UN ANILLO CICLOPROPANO o FORMAN UN =CH2; R3, R4, "A" Y "B" SON COMO SE DEFINIERON PARA (I); "Y" ES H o OSi(CH3)3. LOS COMPUESTOS OBTENIDOS SON USADOS PARA TRATAR LA OSTEOPOROSISTHEY REFER TO COMPOUNDS OF FORMULA (I), WHERE: "X" IS = CH2 OR THEY ARE HYDROGEN; R1 AND R2 ARE OF PREFERENCE H, CF3 OR CH3, or R1 AND R2 TOGETHER WITH CARBON 20 FORM A CYCLOFLUOROALKYL OR CYCLLOALKYL C3-C6, or R1 AND R2 TOGETHER FORMAN = CH2; R3 AND R4 ARE OF PREFERENCE CH3, CF3, CH2CH3, CH2CF3, CF2CH3 AND CF2CF3 or R3 AND R4 TOGETHER WITH CARBON 25 FORM A C3-C9 CYCLOFLUOROALKYL; "A" IS A SINGLE OR DOUBLE LINK; "B" IS A DOUBLE OR TRIPLE LINK; ALWAYS THAT: WHEN "X" IS = CH2, "A" IS A DOUBLE LINK, AND: (i) R3 AND R4 ARE CF3: IF ONE OF R1 AND R2 IS H, THEN THE OTHER IS NOT CH3; (ii) R3 AND R4 ARE C1-C2 ALKYL: IF R2 IS H, THEN, R1 IS NOT CH3; (iii) R3 AND R4 ARE C1-C4 ALKYL: IF R1 IS H, THEN R2 IS NOT CH3; (iv) R1 IS CH3, R2 IS H: IF ONE OF R3 AND R4 IS CF3, THEN THE OTHER IS NOT CH3; (v) WHEN "X" IS H, R3 AND R4 ARE CF3, "A" IS A DOUBLE LINK, "B" IS A TRIPLE LINK: IF R2 IS H, THEN R1 IS NOT CH3. IT ALSO REFERS TO THE PROCEDURE FOR THE PREPARATION OF THE COMPOUNDS (I), WHICH INCLUDES THE ELIMINATION OF THE SILILO PROTECTIVE GROUPS; AND TO THE INTERMEDIATE COMPOUNDS OF FORMULA (II), WHERE: R1 AND R2 ARE CH3 or TOGETHER WITH CARBON 20 FORM A CYCLOPROPAN RING or FORMAN UN = CH2; R3, R4, "A" AND "B" ARE AS DEFINED FOR (I); "Y" IS H or OSi (CH3) 3. THE COMPOUNDS OBTAINED ARE USED TO TREAT OSTEOPOROSIS

PE1997000387A 1996-05-23 1997-05-16 ANALOGS OF VITAMIN D3 TREATED WITH FLUORINE PE66798A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1821996P 1996-05-23 1996-05-23
US3990197P 1997-03-19 1997-03-19

Publications (1)

Publication Number Publication Date
PE66798A1 true PE66798A1 (en) 1998-10-22

Family

ID=26690870

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000387A PE66798A1 (en) 1996-05-23 1997-05-16 ANALOGS OF VITAMIN D3 TREATED WITH FLUORINE

Country Status (26)

Country Link
EP (1) EP0808832B1 (en)
JP (1) JP2859248B2 (en)
KR (1) KR100253961B1 (en)
CN (1) CN100402497C (en)
AR (1) AR007776A1 (en)
AT (1) ATE238278T1 (en)
AU (1) AU733970B2 (en)
BR (1) BR9703385A (en)
CA (1) CA2205315C (en)
CO (1) CO4940503A1 (en)
CZ (1) CZ157797A3 (en)
DE (1) DE69721123T2 (en)
DK (1) DK0808832T3 (en)
ES (1) ES2195049T3 (en)
HR (1) HRP970272A2 (en)
HU (1) HUP9700928A3 (en)
IL (1) IL120844A0 (en)
MA (1) MA24250A1 (en)
NO (1) NO972278L (en)
NZ (1) NZ314840A (en)
PE (1) PE66798A1 (en)
PL (1) PL320130A1 (en)
PT (1) PT808832E (en)
SG (1) SG70010A1 (en)
TR (1) TR199700416A2 (en)
YU (1) YU20097A (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008209A (en) * 1997-04-28 1999-12-28 Hoffmann-La Roche Inc. Method of using vitamin D3 analogs with bis C-20 side chains
DE19935771A1 (en) 1999-07-23 2001-02-01 Schering Ag New vitamin D derivatives with cyclic substructures in the side chains, processes and intermediates for their manufacture and their use in the manufacture of pharmaceuticals
AU2001278744A1 (en) * 2000-08-17 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Remedial agent for osteoporosis
MXPA04002640A (en) * 2001-09-21 2004-06-07 Hoffmann La Roche 3-desoxy-vitamin d3 analog esters.
PT103177A (en) 2003-09-24 2005-03-31 Bioxell Spa 1-ALPHA-FLUORO-25-HYDROXY-16,23E-DIENE-26,27-BIS-HOMO-20-EPI-COLECALCIFEROL, ITS SALTS OR ESTERS AND ITS USE IN THE MANUFACTURE OF MEDICINES
JP2008514621A (en) * 2004-09-24 2008-05-08 ビオクセル エッセ ピ ア 20-Cycloalkyl, 26,27-alkyl / haloalkyl-vitamin D3 compounds and methods of use thereof
US20090099140A1 (en) * 2005-03-23 2009-04-16 Bioxell S.P.A. 20-Alkyl, Gemini Vitamin D3 Compounds and Methods of Use Thereof
EP2634171B8 (en) 2010-10-25 2016-01-13 Teijin Pharma Limited 23-yne-vitamin d3 derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4141746A1 (en) * 1991-12-13 1993-06-17 Schering Ag 20-METHYL-SUBSTITUTED VITAMIN D DERIVATIVES
DE4220757A1 (en) * 1992-06-24 1994-01-05 Schering Ag Derivatives in the vitamin D series with modifications in the 20-position, process for their preparation, intermediates for this process, pharmaceutical preparations containing these derivatives and their use in the manufacture of medicaments
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
US5384314B1 (en) * 1994-03-11 1997-08-05 Hoffmann La Roche 1alpha-fluoro-25-hydroxy-16-ene-23-yne-cholecalciferol
WO1997016193A1 (en) * 1995-10-27 1997-05-09 F. Hoffmann-La Roche Ag Pharmaceutical composition for treating osteoporosis

Also Published As

Publication number Publication date
AU733970B2 (en) 2001-05-31
HRP970272A2 (en) 1998-04-30
DE69721123D1 (en) 2003-05-28
CO4940503A1 (en) 2000-07-24
NZ314840A (en) 1998-11-25
NO972278D0 (en) 1997-05-20
CN100402497C (en) 2008-07-16
HU9700928D0 (en) 1997-07-28
DK0808832T3 (en) 2003-08-11
CA2205315A1 (en) 1997-11-23
DE69721123T2 (en) 2004-01-08
EP0808832A3 (en) 1999-02-03
YU20097A (en) 1999-09-27
CA2205315C (en) 2006-10-24
JPH1045714A (en) 1998-02-17
EP0808832B1 (en) 2003-04-23
KR970074764A (en) 1997-12-10
IL120844A0 (en) 1997-09-30
HUP9700928A3 (en) 1999-07-28
BR9703385A (en) 1998-09-15
TR199700416A2 (en) 1997-12-21
PL320130A1 (en) 1997-11-24
ES2195049T3 (en) 2003-12-01
SG70010A1 (en) 2000-01-25
NO972278L (en) 1997-11-24
PT808832E (en) 2003-07-31
CZ157797A3 (en) 1997-12-17
ATE238278T1 (en) 2003-05-15
AR007776A1 (en) 1999-11-24
MA24250A1 (en) 1998-04-01
EP0808832A2 (en) 1997-11-26
CN1172801A (en) 1998-02-11
HUP9700928A2 (en) 1998-01-28
JP2859248B2 (en) 1999-02-17
MX9703775A (en) 1998-06-30
AU2357697A (en) 1997-11-27
KR100253961B1 (en) 2000-04-15

Similar Documents

Publication Publication Date Title
CO4950531A1 (en) ANALOGS OF VITAMIN D3 PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
ES2055056T3 (en) DERIVATIVES OF PIRIMIDOPIRIMIDINA.
ES481220A1 (en) Novel Aminothiazoles
ES2139943T3 (en) NEW INHIBITORS OF THE PRINT-GLANDINA SINTASA.
ES2174989T3 (en) PIRIDO (3,2-E) PIRAZINONAS WITH ANTIASMATICS AND PROCEDURE FOR PREPARATION.
ES2011210T3 (en) SUBSTITUTED GEM-DIPHOSPHONATE DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ES2045180T3 (en) NEW PROCEDURE FOR THE OBTAINING OF 4-ACILOXI-3-HIDROXIETIL-AZETIDINONAS.
ES526318A0 (en) PROCEDURE FOR THE OBTAINING OF SUBSTITUTED 1-HYDROXYETHYL-TRIAZOLYL DERIVATIVES
AR247402A1 (en) Improved process for preparing macrolide derivatives
ES2117281T3 (en) NEW ANALOGS OF VITAMIN D.
PE66798A1 (en) ANALOGS OF VITAMIN D3 TREATED WITH FLUORINE
AR241593A1 (en) PROCEDURE FOR PREPARING DERIVATIVES OF QUINOLIN-3-CARBOXYLIC ACID.
AR036000A1 (en) PROCESS FOR THE PREPARATION OF INDOL DERIVATIVES AND NOVEDOUS INTERMEDIARIES
ES449096A1 (en) A PROCEDURE FOR THE PREPARATION OF 11-DESOXI-16-ARYLOXI-OMEGA-TETRANORPROSTAGLANDINS.
ES8606382A1 (en) A PROCEDURE FOR PREPARING A 2'-DESOXI-5-SUBSTITUTED URIDINE DERIVATIVE
ES2145563T3 (en) NEW IMIDAZOLINE DERIVATIVES WITH AN AFFINITY FOR IMIDAZOLINE RECEPTORS.
DK121383A (en) PROCEDURE FOR THE PREPARATION OF 8-SUBSTITUTED PYRROLIZIDE INGREDIENTS
SE8003278L (en) phenylethylamine
PT83452A (en) Process for preparing alkylmercaptaophenyl-1,3,4-oxa (or thia) iazole derivatives and nematicidal compositions therewith
AR018675A1 (en) DERIVATIVES OF 3- (2-OXO- [1,3¿I¿] BIPIRROLIDINIL-3-ILIDENOMETIL) -CEFEM, A PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
EA199900460A1 (en) DERIVATIVES OF BENZULSULPHONE AMID AND MEDICINES CONTAINING MENTIFIED DERIVATIVES
ES464796A1 (en) PROCEDURE TO PREPARE SUBSTITUTED PHENYLPHOSPHATES.
AU583247B2 (en) Heteroaryloxypropanolamines
ES520136A0 (en) A PROCEDURE FOR THE PREPARATION OF A DERIVATIVE OF FURILOXAZOLYL-CETICAL ACID
ES2032461T3 (en) PROCEDURE FOR PREPARING DERIVATIVES OF INDOL.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal